| Literature DB >> 26966000 |
Tao Jiang1, Ying Mao2, Wenbin Ma3, Qing Mao4, Yongping You5, Xuejun Yang6, Chuanlu Jiang7, Chunsheng Kang8, Xuejun Li9, Ling Chen10, Xiaoguang Qiu11, Weimin Wang12, Wenbin Li13, Yu Yao14, Shaowu Li15, Shouwei Li16, Anhua Wu17, Ke Sai18, Hongmin Bai12, Guilin Li15, Baoshi Chen19, Kun Yao20, Xinting Wei21, Xianzhi Liu21, Zhiwen Zhang22, Yiwu Dai23, Shengqing Lv24, Liang Wang25, Zhixiong Lin16, Jun Dong26, Guozheng Xu27, Xiaodong Ma10, Jinquan Cai7, Wei Zhang19, Hongjun Wang7, Lingchao Chen14, Chuanbao Zhang15, Pei Yang15, Wei Yan28, Zhixiong Liu9, Huimin Hu15, Jing Chen15, Yuqing Liu15, Yuan Yang29, Zheng Wang15, Zhiliang Wang19, Yongzhi Wang19, Gan You19, Lei Han8, Zhaoshi Bao19, Yanwei Liu15, Yinyan Wang19, Xing Fan19, Shuai Liu30, Xing Liu19, Yu Wang30, Qixue Wang8.
Abstract
The Chinese Glioma Cooperative Group (CGCG) Guideline Panel for adult diffuse gliomas provided recommendations for diagnostic and therapeutic procedures. The Panel covered all fields of expertise in neuro-oncology, i.e. neurosurgeons, neurologists, neuropathologists, neuroradiologists, radiation and medical oncologists and clinical trial experts. The task made clearer and more transparent choices about outcomes considered most relevant through searching the references considered most relevant and evaluating their value. The scientific evidence of papers collected from the literature was evaluated and graded based on the Oxford Centre for Evidence-based Medicine Levels of Evidence and recommendations were given accordingly. The recommendations will provide a framework and assurance for the strategy of diagnostic and therapeutic measures to reduce complications from unnecessary treatment and cost. The guideline should serve as an application for all professionals involved in the management of patients with adult diffuse glioma and also as a source of knowledge for insurance companies and other institutions involved in the cost regulation of cancer care in China.Entities:
Keywords: CGCG; Glioma; Guideline; Management
Mesh:
Year: 2016 PMID: 26966000 DOI: 10.1016/j.canlet.2016.01.024
Source DB: PubMed Journal: Cancer Lett ISSN: 0304-3835 Impact factor: 8.679